Results 101 to 110 of about 62,795 (319)
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report
Frontiers in OncologyIntroductionRegorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic gastrointestinal stromal tumors (GIST), as a third-line systemic therapy.
Elena Fassi +6 more
doaj +1 more source
A case of heart failure and polycythemia: Treated with phlebotomy
Journal of the Practice of Cardiovascular Sciences, 2020 Polycythemia in heart failure (HF) is known but rarely encountered. A 76-year-old male presented with New York Heart Association Class III HF symptoms leading to secondary polycythemia.
Ashwin Kodliwadmath, Dibbendhu Khanra
doaj +1 more source
Safety of delayed umbilical cord clamping in preterm neonates of less than 34 weeks of gestation: a randomized controlled trial [PDF]
Obstetrics & Gynecology Science, 2018 ObjectiveThere is concern regarding the safety of delayed cord clamping (DCC) in babies born at less than 34 weeks' gestation. Therefore, the primary objective of this study was to compare the rates of hyperbilirubinemia and polycythemia during initial 7
Anubhuti Rana +4 more
doaj +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Updates in the management of polycythemia vera and essential thrombocythemia
Therapeutic Advances in Hematology, 2019 Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar +1 more source
Expert Perspective: Hematologic Malignancies and Vasculitis
Arthritis &Rheumatology, EarlyView.
Michelle L. Robinette, Hetty E. Carraway
wiley +1 more source
Primary myelofibrosis with increased haemoglobin concentration at presentation
British Journal of Haematology, EarlyView.Subjects with primary myelofibrosis and elevated haemoglobin levels at diagnosis tend to have longer survival rates (OS) and blast transformation‐free survival (BTFS) than those with normal or reduced haemoglobin levels. Summary One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin ...
Giovanni Barosi +8 more
wiley +1 more source
THE CONTROL OF POLYCYTHEMIA BY MARROW INHIBITION [PDF]
, 1949 John H. Lawrence
openalex +2 more sources
International Journal of COPD, 2022 Zhaofu Zeng, Yan Song, Xin He, Haizhen Yang, Fang Yue, Mengqing Xiong, Ke Hu Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of ChinaCorrespondence: Ke HuDepartment of Respiratory and ...
Zeng Z +6 more
doaj
Coexisting Cardiac and Hematologic Disorders. [PDF]
, 2016 Patients with concomitant cardiac and hematologic disorders presenting for noncardiac surgery are challenging. Anemic patients with cardiac disease should be approached in a methodical fashion.
Goldhammer, Jordan E., Kohl, Benjamin A.
core +3 more sources